

COMPANY OVERVIEW

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen's three drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets.

RECENT NEWS

VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

Jan 6 2021, 8:00 AM EST

STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	329.18m
Last Price	\$2.40
52-Week Range	\$0.31 - \$2.42

01/15/2021 04:00 PM EST

INVESTOR RELATIONS

VistaGen Therapeutics, Inc.
Mark A. McPartland
Vice President, Corporate Development
and Investor Relations
(650) 577-3606
markmcp@vistagen.com

MANAGEMENT TEAM

Shawn K. Singh, J.D.
Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.
Founder, President, Chief Scientific Officer
and Director

Mark A. Smith, M.D., Ph.D.
Chief Medical Officer

Jerrold D. Dotson, CPA
Vice President, Chief Financial Officer and
Secretary

Mark A. McPartland
Vice President of Corporate Development

Louis Monti, M.D., Ph.D.
Vice President, Translational Medicine

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.